ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

CHB Global X China Biotech Innovations ETF

6.64
0.00 (0.00%)
Last Updated: 01:00:00
Delayed by 15 minutes
Name Symbol Market Type
Global X China Biotech Innovations ETF NASDAQ:CHB NASDAQ Exchange Traded Fund
  Price Change % Change Price Bid Price Offer Price High Price Low Price Open Price Traded Last Trade
  0.00 0.00% 6.64 2.67 10.66 0 01:00:00

Rule 8 - Chubb Plc

16/07/2003 8:00am

UK Regulatory


RNS Number:5985N
UBS Limited
16 July 2003

Date of disclosure...16 July 2003


DISCLOSURE UNDER RULES 8.1(a), 8.1(b)(i) AND 8.3
OF THE CITY CODE ON TAKEOVERS AND MERGERS

Date of dealing ...15 July 2003


Dealing in ... Chubb plc ......................................(name of company)


(1)  Class of securities (eg ordinary shares) ........................ORD 36p

(2)  Amount bought            Amount sold              Price per unit

      40,000,000                                            76.0p


(3)       Resultant total of the same class owned or controlled
          (and percentage of class)    ( %)

          83,070,990 (10.02%)


(4)       Party making disclosure ... UBS Limited


(5)      EITHER   (a)   Name of purchaser/vendor (Note 1) ...Ceesail Limited

         OR       (b)        If dealing for discretionary client(s), name of 
                             fund management organisation

(6)    Reason for disclosure (Note 2)

       (a)  associate of  (i)  offeror (Note 3)  YES  (ii)  offeree company   NO

            Specify which category or categories of associate (1-8 overleaf) 1

            If category (8), explain



       (b)               Rule 8.3 (ie disclosure because of ownership or
        control of 1% or more of the class of relevant securities dealt in)  NO



Signed, for and on behalf of the party named in (4) above .......... n/a

(Also print name of signatory) ........................Philip Ellick

Telephone and extension number ........................020 7568 4161

______________________________________

Note 1.   Specify owner, not nominee or vehicle company. If relevant, also
identify controller of owner, eg where an owner normally acts on instructions of
a controller.

Note 2.   Disclosure might be made for more than one reason; if so, state all 
reasons.

Note 3.   Specify which offeror if there is more than one.

Note 4.   When an arrangement exists with any offeror, with the offeree company
or with an associate of any offeror or of the offeree company in relation to
relevant securities, details of such arrangement must be disclosed, as required
by Note 6 on Rule 8.

Note 5.   It may be necessary, particularly when disclosing derivative
transactions, to append a sheet to this disclosure form so that all relevant
information can be given.

Note 6.  In the case of an average price bargain, each underlying trade should
be disclosed.

For full details of disclosure requirements, see Rule 8 of the Code. If in
doubt, contact the Panel on Takeovers and Mergers, Monitoring Section, Tel. No:
020 7638 0129.




                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

DCCEAPXSFSLDEFE

1 Year Global X China Biotech I... Chart

1 Year Global X China Biotech I... Chart

1 Month Global X China Biotech I... Chart

1 Month Global X China Biotech I... Chart

Your Recent History

Delayed Upgrade Clock